FibroGen, Inc. (NASDAQ:FGEN) is a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for anemia, fibrotic disease, and cancer. The company has announced a significant corporate action: a 1-for-25 reverse stock split, set to take effect at 5:00 p.m. Eastern Time on June 16, 2025.

This strategic move aims to increase the stock price by reducing the number of shares available, potentially making the stock more attractive to investors. Here's what you need to know about this upcoming change:

- The reverse stock split will result in shareholders receiving 1 share for every 25 shares they currently own. - Currently, FGEN's stock is priced at $0.26, having decreased by 14.46% with a change of -$0.04. - The market capitalization of FGEN is approximately $26.67 million, with a trading volume of 3,900,845 shares on the NASDAQ exchange.

The reverse stock split is a critical step for FibroGen as it seeks to stabilize its stock price and enhance shareholder value. By consolidating shares, the company aims to make its stock more appealing to a broader range of investors. Trading on a split-adjusted basis will commence the day following the split, under the same ticker symbol but with a new CUSIP number, 31572Q881, to reflect the change. This adjustment could have significant implications for the company's stock performance and investor interest moving forward.